Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Immunex Novantrone MS Use Is Likely To Be Second-Line

Executive Summary

Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.

You may also be interested in...

Immunex Novantrone Proposed Labeling For MS Indication

"Novantrone is indicated for the treatment of patients with secondary progressive multiple sclerosis, including progressive relapsing disease. Novantrone has been shown to slow the progression of physical disability and neurologic impairment, reduce the frequency of clinical relapse, increase the time to the first treated relapse, and reduce the number of hospitalizations.

Schering AG U.S. Expansion Plans Call For Sales Of $1.6 Bil. In 2005

Schering AG expects its U.S. business to approach $1.6 bil. in revenues by 2005, more than double its projected 1999 level of $750 mil.

AHP Enbrel Market Expansion Plans Include Up To 2.4 Mil. U.S. Patients

The next step in Wyeth-Ayerst's plans to expand the market for Enbrel will be the presentation of the pivotal trial data in early rheumatoid arthritis during the upcoming American College of Rheumatology conference in Boston, Nov. 13-17.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts